GSK’s Acquisition of RAPT Therapeutics Nears Completion

The planned acquisition of RAPT Therapeutics by pharmaceutical giant GSK is entering its final stages. As the deal progresses toward a conclusion, investor focus is shifting to key deadlines and the potential of the company’s immunology-focused drug pipeline.

Key Dates and Deal Structure

A pivotal date in this process is March 2, 2026, which marks the expiration of the tender offer period. GSK has stated its intention to finalize the acquisition within the first quarter of this year, assuming all customary closing conditions are satisfied.

This transaction is undergoing standard legal reviews by shareholder law firms. These routine examinations, common for deals of this scale, assess the fairness of the transaction’s structure to the company’s equity holders. Their findings are a critical component for the deal’s final implementation.

Should investors sell immediately? Or is it worth buying RAPT Therapeutics?

Clinical Focus and Upcoming Catalysts

The scientific cornerstone of RAPT’s appeal is its drug candidate, ozureprubart. This long-acting antibody is designed to provide prophylactic protection for patients against food allergens. A primary goal of its development is to significantly extend the intervals between required doses compared to existing standard therapies.

Should this approach prove successful in clinical trials, it has the potential to fundamentally reshape treatment protocols in the allergy sector. The market for such innovative therapies is currently viewed as highly dynamic, which explains why specialized firms like RAPT attract attention from larger industry players.

The company is scheduled to release its quarterly financial results in early March, offering further insight into its operational standing. However, the long-term clinical valuation hinges substantially on data from the Phase 2b study for ozureprubart, anticipated in 2027. Until then, the successful closing of the transaction with GSK remains the dominant factor guiding the company’s near-term trajectory.